Report cover image

Global Tumour Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 192 Pages
SKU # APRC20356019

Description

Summary

According to APO Research, The global Tumour Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Tumour Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Tumour Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Tumour Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Tumour Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Tumour Vaccine include Advaxis, Agenus Inc, Avidea Technologies, BioNTech, BrightPath Biotherapeutics, Genocea Biosciences Inc, Gritstone Bio, ISA Pharmaceuticals and Medigene AG, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Tumour Vaccine, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Tumour Vaccine, also provides the revenue of main regions and countries. Of the upcoming market potential for Tumour Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Tumour Vaccine revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Tumour Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Tumour Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Tumour Vaccine Segment by Company

Advaxis
Agenus Inc
Avidea Technologies
BioNTech
BrightPath Biotherapeutics
Genocea Biosciences Inc
Gritstone Bio
ISA Pharmaceuticals
Medigene AG
Moderna
Nouscom
Novogene
OSE Immunotherapeutics
Roche Holding AG
Vaccibody AS
Vaximm AG
ZIOPHARM Oncology
Pfizer
Eli Lilly and Company
Merck & Co Inc
Tumour Vaccine Segment by Type

Personalized Vaccine
Off-the shelf Vaccine
Tumour Vaccine Segment by Application

Gastrointestinal Cancer
Lung Cancer
Melanoma Cancer
Brain Cancer
Others
Tumour Vaccine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumour Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumour Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumour Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Tumour Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tumour Vaccine industry.
Chapter 3: Detailed analysis of Tumour Vaccine companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tumour Vaccinerevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Market Analysis by Type
1.2.1 Global Tumour Vaccine Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Personalized Vaccine
1.2.3 Off-the shelf Vaccine
1.3 Market Analysis by Application
1.3.1 Global Tumour Vaccine Market Size Growth Rate by Application: 2020 VS 2024 VS 2031
1.3.2 Gastrointestinal Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma Cancer
1.3.5 Brain Cancer
1.3.6 Others
1.4 Global Market Growth Prospects
1.5 Global Tumour Vaccine Growth Trends by Region
1.5.1 Global Tumour Vaccine Market Size by Region: 2020 VS 2024 VS 2031
1.5.2 Tumour Vaccine Market Size by Region (2020-2025)
1.5.3 Tumour Vaccine Market Size by Region (2026-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
1.8 Years Considered
2 Global Tumour Vaccine Market Dynamics
2.1 Tumour Vaccine Industry Trends
2.2 Tumour Vaccine Industry Drivers
2.3 Tumour Vaccine Industry Opportunities and Challenges
2.4 Tumour Vaccine Industry Restraints
3 Competitive Landscape by Company
3.1 Global Tumour Vaccine Revenue by Company (2020-2025)
3.2 Global Tumour Vaccine Players Revenue Ranking, 2023 VS 2024 VS 2025
3.3 Global Tumour Vaccine Key Company Head office and Area Served
3.4 Global Tumour Vaccine Company, Product Type & Application
3.5 Global Tumour Vaccine Company Establishment Date
3.6 Market Competitive Analysis
3.6.1 Global Tumour Vaccine Market CR5 and HHI
3.6.2 Global Top 5 and 10 Tumour Vaccine Players Market Share by Revenue in 2024
3.6.3 2024 Tumour Vaccine Tier 1, Tier 2, and Tier 3
4 Tumour Vaccine Market by Type
4.1 Global Tumour Vaccine Market Size by Type (2020 VS 2024 VS 2031)
4.2 Global Tumour Vaccine Market Size by Type (2020-2031)
4.3 Global Tumour Vaccine Market Size Share by Type (2020-2031)
5 Tumour Vaccine Market by Application
5.1 Global Tumour Vaccine Market Size by Application (2020 VS 2024 VS 2031)
5.2 Global Tumour Vaccine Market Size by Application (2020-2031)
5.3 Global Tumour Vaccine Market Size Share by Application (2020-2031)
6 Company Profiles
6.1 Advaxis
6.1.1 Advaxis Comapny Information
6.1.2 Advaxis Business Overview
6.1.3 Advaxis Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.1.4 Advaxis Tumour Vaccine Product Portfolio
6.1.5 Advaxis Recent Developments
6.2 Agenus Inc
6.2.1 Agenus Inc Comapny Information
6.2.2 Agenus Inc Business Overview
6.2.3 Agenus Inc Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.2.4 Agenus Inc Tumour Vaccine Product Portfolio
6.2.5 Agenus Inc Recent Developments
6.3 Avidea Technologies
6.3.1 Avidea Technologies Comapny Information
6.3.2 Avidea Technologies Business Overview
6.3.3 Avidea Technologies Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.3.4 Avidea Technologies Tumour Vaccine Product Portfolio
6.3.5 Avidea Technologies Recent Developments
6.4 BioNTech
6.4.1 BioNTech Comapny Information
6.4.2 BioNTech Business Overview
6.4.3 BioNTech Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.4.4 BioNTech Tumour Vaccine Product Portfolio
6.4.5 BioNTech Recent Developments
6.5 BrightPath Biotherapeutics
6.5.1 BrightPath Biotherapeutics Comapny Information
6.5.2 BrightPath Biotherapeutics Business Overview
6.5.3 BrightPath Biotherapeutics Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.5.4 BrightPath Biotherapeutics Tumour Vaccine Product Portfolio
6.5.5 BrightPath Biotherapeutics Recent Developments
6.6 Genocea Biosciences Inc
6.6.1 Genocea Biosciences Inc Comapny Information
6.6.2 Genocea Biosciences Inc Business Overview
6.6.3 Genocea Biosciences Inc Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.6.4 Genocea Biosciences Inc Tumour Vaccine Product Portfolio
6.6.5 Genocea Biosciences Inc Recent Developments
6.7 Gritstone Bio
6.7.1 Gritstone Bio Comapny Information
6.7.2 Gritstone Bio Business Overview
6.7.3 Gritstone Bio Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.7.4 Gritstone Bio Tumour Vaccine Product Portfolio
6.7.5 Gritstone Bio Recent Developments
6.8 ISA Pharmaceuticals
6.8.1 ISA Pharmaceuticals Comapny Information
6.8.2 ISA Pharmaceuticals Business Overview
6.8.3 ISA Pharmaceuticals Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.8.4 ISA Pharmaceuticals Tumour Vaccine Product Portfolio
6.8.5 ISA Pharmaceuticals Recent Developments
6.9 Medigene AG
6.9.1 Medigene AG Comapny Information
6.9.2 Medigene AG Business Overview
6.9.3 Medigene AG Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.9.4 Medigene AG Tumour Vaccine Product Portfolio
6.9.5 Medigene AG Recent Developments
6.10 Moderna
6.10.1 Moderna Comapny Information
6.10.2 Moderna Business Overview
6.10.3 Moderna Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.10.4 Moderna Tumour Vaccine Product Portfolio
6.10.5 Moderna Recent Developments
6.11 Nouscom
6.11.1 Nouscom Comapny Information
6.11.2 Nouscom Business Overview
6.11.3 Nouscom Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.11.4 Nouscom Tumour Vaccine Product Portfolio
6.11.5 Nouscom Recent Developments
6.12 Novogene
6.12.1 Novogene Comapny Information
6.12.2 Novogene Business Overview
6.12.3 Novogene Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.12.4 Novogene Tumour Vaccine Product Portfolio
6.12.5 Novogene Recent Developments
6.13 OSE Immunotherapeutics
6.13.1 OSE Immunotherapeutics Comapny Information
6.13.2 OSE Immunotherapeutics Business Overview
6.13.3 OSE Immunotherapeutics Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.13.4 OSE Immunotherapeutics Tumour Vaccine Product Portfolio
6.13.5 OSE Immunotherapeutics Recent Developments
6.14 Roche Holding AG
6.14.1 Roche Holding AG Comapny Information
6.14.2 Roche Holding AG Business Overview
6.14.3 Roche Holding AG Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.14.4 Roche Holding AG Tumour Vaccine Product Portfolio
6.14.5 Roche Holding AG Recent Developments
6.15 Vaccibody AS
6.15.1 Vaccibody AS Comapny Information
6.15.2 Vaccibody AS Business Overview
6.15.3 Vaccibody AS Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.15.4 Vaccibody AS Tumour Vaccine Product Portfolio
6.15.5 Vaccibody AS Recent Developments
6.16 Vaximm AG
6.16.1 Vaximm AG Comapny Information
6.16.2 Vaximm AG Business Overview
6.16.3 Vaximm AG Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.16.4 Vaximm AG Tumour Vaccine Product Portfolio
6.16.5 Vaximm AG Recent Developments
6.17 ZIOPHARM Oncology
6.17.1 ZIOPHARM Oncology Comapny Information
6.17.2 ZIOPHARM Oncology Business Overview
6.17.3 ZIOPHARM Oncology Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.17.4 ZIOPHARM Oncology Tumour Vaccine Product Portfolio
6.17.5 ZIOPHARM Oncology Recent Developments
6.18 Pfizer
6.18.1 Pfizer Comapny Information
6.18.2 Pfizer Business Overview
6.18.3 Pfizer Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.18.4 Pfizer Tumour Vaccine Product Portfolio
6.18.5 Pfizer Recent Developments
6.19 Eli Lilly and Company
6.19.1 Eli Lilly and Company Comapny Information
6.19.2 Eli Lilly and Company Business Overview
6.19.3 Eli Lilly and Company Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.19.4 Eli Lilly and Company Tumour Vaccine Product Portfolio
6.19.5 Eli Lilly and Company Recent Developments
6.20 Merck & Co Inc
6.20.1 Merck & Co Inc Comapny Information
6.20.2 Merck & Co Inc Business Overview
6.20.3 Merck & Co Inc Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2020-2025)
6.20.4 Merck & Co Inc Tumour Vaccine Product Portfolio
6.20.5 Merck & Co Inc Recent Developments
7 North America
7.1 North America Tumour Vaccine Market Size (2020-2031)
7.2 North America Tumour Vaccine Market Size by Type
7.2.1 North America Tumour Vaccine Market Size by Type (2020-2025)
7.2.2 North America Tumour Vaccine Market Size by Type (2026-2031)
7.2.3 North America Tumour Vaccine Market Share by Type (2020-2031)
7.3 North America Tumour Vaccine Market Size by Application
7.3.1 North America Tumour Vaccine Market Size by Application (2020-2025)
7.3.2 North America Tumour Vaccine Market Size by Application (2026-2031)
7.3.3 North America Tumour Vaccine Market Share by Application (2020-2031)
7.4 North America Tumour Vaccine Market Size by Country
7.4.1 North America Tumour Vaccine Market Size by Country (2020 VS 2024 VS 2031)
7.4.2 North America Tumour Vaccine Market Size by Country (2020-2025)
7.4.3 North America Tumour Vaccine Market Size by Country (2026-2031)
7.4.4 North America Tumour Vaccine Market Share by Country (2020-2031)
7.4.5 United States
7.4.6 Canada
7.4.7 Mexico
8 Europe
8.1 Europe Tumour Vaccine Market Size (2020-2031)
8.2 Europe Tumour Vaccine Market Size by Type
8.2.1 Europe Tumour Vaccine Market Size by Type (2020-2025)
8.2.2 Europe Tumour Vaccine Market Size by Type (2026-2031)
8.2.3 Europe Tumour Vaccine Market Share by Type (2020-2031)
8.3 Europe Tumour Vaccine Market Size by Application
8.3.1 Europe Tumour Vaccine Market Size by Application (2020-2025)
8.3.2 Europe Tumour Vaccine Market Size by Application (2026-2031)
8.3.3 Europe Tumour Vaccine Market Share by Application (2020-2031)
8.4 Europe Tumour Vaccine Market Size by Country
8.4.1 Europe Tumour Vaccine Market Size by Country (2020 VS 2024 VS 2031)
8.4.2 Europe Tumour Vaccine Market Size by Country (2020-2025)
8.4.3 Europe Tumour Vaccine Market Size by Country (2026-2031)
8.4.4 Europe Tumour Vaccine Market Share by Country (2020-2031)
8.4.5 Germany
8.4.6 France
8.4.7 U.K.
8.4.8 Italy
8.4.9 Russia
8.4.10 Nordic Countries
9 China
9.1 China Tumour Vaccine Market Size (2020-2031)
9.2 China Tumour Vaccine Market Size by Type
9.2.1 China Tumour Vaccine Market Size by Type (2020-2025)
9.2.2 China Tumour Vaccine Market Size by Type (2026-2031)
9.2.3 China Tumour Vaccine Market Share by Type (2020-2031)
9.3 China Tumour Vaccine Market Size by Application
9.3.1 China Tumour Vaccine Market Size by Application (2020-2025)
9.3.2 China Tumour Vaccine Market Size by Application (2026-2031)
9.3.3 China Tumour Vaccine Market Share by Application (2020-2031)
10 Asia (Excluding China)
10.1 Asia Tumour Vaccine Market Size (2020-2031)
10.2 Asia Tumour Vaccine Market Size by Type
10.2.1 Asia Tumour Vaccine Market Size by Type (2020-2025)
10.2.2 Asia Tumour Vaccine Market Size by Type (2026-2031)
10.2.3 Asia Tumour Vaccine Market Share by Type (2020-2031)
10.3 Asia Tumour Vaccine Market Size by Application
10.3.1 Asia Tumour Vaccine Market Size by Application (2020-2025)
10.3.2 Asia Tumour Vaccine Market Size by Application (2026-2031)
10.3.3 Asia Tumour Vaccine Market Share by Application (2020-2031)
10.4 Asia Tumour Vaccine Market Size by Country
10.4.1 Asia Tumour Vaccine Market Size by Country (2020 VS 2024 VS 2031)
10.4.2 Asia Tumour Vaccine Market Size by Country (2020-2025)
10.4.3 Asia Tumour Vaccine Market Size by Country (2026-2031)
10.4.4 Asia Tumour Vaccine Market Share by Country (2020-2031)
10.4.5 Japan
10.4.6 South Korea
10.4.7 Taiwan
10.4.8 Southeast Asia
10.4.9 India
10.4.10 Australia
11 South America, Middle East & Africa
11.1 South America, Middle East & Africa Tumour Vaccine Market Size (2020-2031)
11.2 South America, Middle East & Africa Tumour Vaccine Market Size by Type
11.2.1 South America, Middle East & Africa Tumour Vaccine Market Size by Type (2020-2025)
11.2.2 South America, Middle East & Africa Tumour Vaccine Market Size by Type (2026-2031)
11.2.3 South America, Middle East & Africa Tumour Vaccine Market Share by Type (2020-2031)
11.3 South America, Middle East & Africa Tumour Vaccine Market Size by Application
11.3.1 South America, Middle East & Africa Tumour Vaccine Market Size by Application (2020-2025)
11.3.2 South America, Middle East & Africa Tumour Vaccine Market Size by Application (2026-2031)
11.3.3 South America, Middle East & Africa Tumour Vaccine Market Share by Application (2020-2031)
11.4 South America, Middle East & Africa Tumour Vaccine Market Size by Country
11.4.1 South America, Middle East & Africa Tumour Vaccine Market Size by Country (2020 VS 2024 VS 2031)
11.4.2 South America, Middle East & Africa Tumour Vaccine Market Size by Country (2020-2025)
11.4.3 South America, Middle East & Africa Tumour Vaccine Market Size by Country (2026-2031)
11.4.4 South America, Middle East & Africa Tumour Vaccine Market Share by Country (2020-2031)
11.4.5 Brazil
11.4.6 South Africa
11.4.7 Saudi Arabia
11.4.8 Turkey
11.4.9 Argentina
11.4.9 UAE
11.4.9 Egypt
11.4.9 Chile
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
13.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.